Salvador Martín, SaraKaczmarczyk, BartoszAlvarez, RebecaNavas López, Víctor ManuelGallego Fernández, CarmenMoreno Álvarez, AnaSolar Boga, AlfonsoSánchez Sánchez, CésarTolin, MarVelasco, MartaMuñoz Codoceo, RosanaRodriguez Martinez, AlejandroVayo, Concepción A.Bossacoma, FerránPujol Muncunill, GemmaFobelo, María J.Millán Jiménez, AntonioMagallares, LorenaMartínez Ojinaga, EvaLoverdos, InésEizaguirre, Francisco J.Blanca García, José A.Clemente, SusanaGarcía Romero, RuthMerino Bohórquez, VicenteGonzález de Caldas, RafaelVázquez, EnriqueDopazo, AnaSanjurjo Sáez, MaríaLópez Fernández, Luis Andrés2023-06-172023-06-172021-01-061999-492310.3390/pharmaceutics13010077https://hdl.handle.net/20.500.14352/7427Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/pharmaceutics13010077https://www.mdpi.com/journal/pharmaceuticsopen access615.01/.03616.3BiomarkerGene expressionInfliximabAdalimumabUlcerative colitisCrohn diseaseInflammatory bowel diseaseMedicinaFarmacología (Medicina)Gastroenterología y hepatologíaPediatría32 Ciencias Médicas3205.03 Gastroenterología3201.10 Pediatría